An approach to individualised therapy of Non-Small Cell Ling Carcinoma (NSCLC) - Relevance of molecular predictive and prognostic factors;Auf dem Weg zu einer individualisierten Therapie des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) - Stellenwert molekularer prädiktions- und prognosefaktoren

Pneumologie

Volumn 61, Issue 11, 2007, Pages 731-740

  Zirlik, S ^a   Lampert, S ^a   Hahn, E G ^a   Wiest, G H ^b   Brückl, Wolfgang M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Asklepios Klinik Harburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MOLECULAR MARKER; PROTEIN RRM1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PALLIATIVE CARE; PNEUMONECTOMY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 36749103137     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-980130     Document Type: Review

References (103)

1. Nakamura H, Saji H, Ogata A et al. cDNA microarray analysis of gene expression in pathologic Stage IA nonsmall cell lung carcinomas. Cancer 2003; 97: 2798-2805
2. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005; 366: 1385-1396
3. Brambilla E, Travis WD, Colby TV et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18: 1059-1068
4. Tomida S, Koshikawa K, Yatabe Y et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23: 5360-5370
5. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597
6. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727
7. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360
8. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734-1742
9. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463-2472
10. Croner RS, Foertsch T, Siebenhaar R et al. Tissue preparation for gene expression profiling of colorectal carcinoma: Three alternatives to laser microdissection with preamplification. J Lab Clin Med 2004; 143: 344-351
11. Hofmann W-KOOG, Hoelzer D. Globale Genexpressionsanalyse mit Microarrays. Deutsches Ärzteblatt 2003; 5: 243-246
12. Veer LJ van't, Dai H, Vijver MJ van de et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536
13. Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54
14. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537
15. Croner RS, Foertsch T, Brueckl WM et al. Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis 2005; 20: 353-362
16. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511
17. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355: 570-580
18. Hermanek P, Mansmann U. Criteria for evaluating prognostic factors. Chirurg 2001; 72: 474-480
19. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 1998; 52: 305-319
20. Adler AS, Chang HY. From description to causality: mechanisms of gene expression signatures in cancer. Cell Cycle 2006; 5: 1148-1151
21. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001; 98: 13784-13789
22. Nacht M, Dracheva T, Gao Y et al. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A 2001; 98: 15 203-15 208
23. Virtanen C, Ishikawa Y, Honjoh D et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci U S A 2002; 99: 12 357-12 362
24. Borczuk AC, Gorenstein L, Walter KL et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003; 163: 1949-1960
25. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144
26. Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12: 713-718
27. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550
28. Sandler AB. Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions. Oncology 2006; 20: 626-628
29. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191
30. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717
31. Bolliger CT, Perruchoud AP. Functional evaluation of the lung resection candidate. Eur Respir J 1998; 11: 198-212
32. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356: 11-20
33. Kassam F, Shepherd FA, Johnston M et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007; 2: 39-43
34. Pignon JP, Tribodet H, Scagliotti GV et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clicial trials including 4,584 patients. Proc Am Soc Clin Oncol 2006; 24: 366s
35. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer - how to handle stage I disease. Oncologist 2007; 12: 331-337
36. Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1N0, T1N1, or T2N0 squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771. Chest 1994; 106: 287S-292S
37. Naruke T. Surgery in locally advanced non-small cell lung cancer. Lung Cancer 2003; 42 Suppl 2: S11-15
38. Serke M. Pharmacologic treatment of bronchial cancer. Part 1: Standards. Pneumologie 2006; 60: 493-508
39. Cecere F, Bria E, Resell R. DNA repair by ERCC1 in non-small-cell lung cancer. N Engl J Med 2006; 355: 2590-2591 author reply 2591
40. Grenader T, Shavit L. DNA repair by ERCC1 in non-small-cell lung cancer. N Engl J Med 2006; 355: 2591
41. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005; 11: 6100-6102
42. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316
43. Dabholkar M, Vionnet J, Bostick-Bruton F et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-708
44. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291
45. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991
46. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 2007; 13: 284-289
47. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-808
48. Bepler G. Using translational research to tailor the use of chemotherapy in the treatment of NSCLC. Lung Cancer 2005; 50 Suppl 1: S13-34
49. Chou TY, Chiu CH, Li LH et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 3750-3757
50. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Bmj 1995; 311: 899-909
51. Huber RM. Lung cancer. Internist 2006; 47: 611-620 quiz 621
52. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31: 68-74
53. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103
54. Shepherd FA, Rodrigues PereiraJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132
55. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597
56. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 2003; 30: 23-31
57. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838-4848
58. Pollack VA, Savage DM, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-748
59. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643
60. Gamou S, Hunts J, Harigai H et al. Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells. Cancer Res 1987; 47: 2668-2673
61. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346
62. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943
63. Marchetti A, Martella C, Felicioni L et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 857-865
64. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520
65. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-8923
66. Jackman DM, Yeap BY, Sequist LV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 3908-3914
67. Riely GJ, Pao W. Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important? Cancer Biol Ther 2005; 4: 1096-1097
68. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655
69. Han SW, Kim TY, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-2501
70. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-6837
71. Taron M, Ichinose Y, Resell R et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11: 5878-5885
72. Zhang XT, Li LY, Mu XL et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 2005; 16: 1334-1342
73. Cortese JF, Gowda AL, Wali A et al. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006; 118: 521-522
74. Asahina H, Yamazaki K, Kinoshita I et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95: 998-1004
75. Rosell R, Taron M, Sanchez JJ et al. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncol 2007; 3: 277-283
76. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-3346
77. Paz-Ares L, Sanchez IM, Garcia-Velasco A et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine kinase domain of the EGF-R Proc. ASCO 2006; 24: 7020
78. Sequist LV, Bell DW, Lynch TJ et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587-595
79. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792
80. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
81. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102: 7665-7670
82. Han SW, Kim TY, Jeon YK et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006; 12: 2538-2544
83. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17
84. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909
85. Hirsch FR, Bunn JrPA. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol 2005; 23: 9044-9047
86. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-8092
87. Mukohara T, Engelman JA, Hanna NH et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97: 1185-1194
88. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab inpatients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24: 5253-5258
89. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429
90. Falck J, Petrini JH, Williams BR et al. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002; 30: 290-394
91. Das AK, Sato M, Story MD et al. Non-Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation. Cancer Res 2006; 66: 9601-9608
92. Raben D, Helfrich B, Chan DC et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11: 795-805
93. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578
94. Rosell R, Cobo M, Isla D et al. Pharmacogenomics and gemcitabine. Ann Oncol 2006; 17 Suppl 5: v13-v16
95. Rosell R, Crino L, Danenberg K et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol 2003; 30: 19-25
96. Shepherd FA, Rosell R. Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer. J Thorac Oncol 2007; 2: 68-76
97. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-1325
98. Simon G, Sharma A, Li X et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 2741-2746
99. Cobo M, Gutierrez V, Alcaide J et al. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer 2007; 56: 255-262
100. Cobo M, Isla D, Massuti B et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754
101. Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005; 5: 73-88
102. Seve P, Isaac S, Tredan O et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481-5486
103. Seve P, Mackey J, Isaac S et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4: 2001-2007